Indigotindisulfonate sodium 0.8% not checked
FollowEvery change as it happens, and a Monday email
Trials
2 active
3 in total
Targets
—
None known yet
What this is
- How it works
- Diagnostic Dye FDA class
- How it’s given
- “Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.”In the company’s words, NCT06085183 on ClinicalTrials.gov
- Tested for
- Ureter Injury (2 trials)
- Main trialPhase 4
- “This is an open label, randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Indigotindisulfonate Sodium Injection, USP 0.8% when used as an aid in the determination of ureteral patency in patients with different degrees of renal impairment.”In the company’s words, NCT06085183 on ClinicalTrials.gov
- Other names
- Bludigo
Other drugs for Ureter Injury
- LY4101174Eli Lilly · Phase 1
- LY4052031Eli Lilly · Phase 1
- VepugratinibEli Lilly · Phase 1
Coming up2
- 30 DecPhase 4 trial completes · ClinicalTrials.gov
- DecPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 30 Dec 2026 | Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment | |
| Phase 3Not yet recruiting | Dec 2026 | Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric Patients | |
| Phase 4Completed | 30 Mar 2026 | Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026